Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Part, Phase 3, Randomized, Observer Blinded Study to Evaluate the Safety and Immunogenicity of Omicron Subvariant and Bivalent SARS-CoV-2 rS Vaccines in Adults Previously Vaccinated With Other COVID-19 Vaccines

NCT05372588 is registered in ClinicalTrials.gov with Novavax as lead sponsor.

NCT NCT05372588
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05372588 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Part, Phase 3, Randomized, Observer Blinded Study to Evaluate the Safety and Immunogenicity of Omicron Subvariant and Bivalent SARS-CoV-2 rS Vaccines in Adults Previously Vaccinated With Other COVID-19 Vaccines
Lead sponsor
Novavax
Phase
Phase 3
Overall status
Completed
Start date
May 25, 2022
Completion date
April 7, 2024
Enrollment
1,340 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, sars cov 2 infection